Market revenue in 2023 | USD 137.6 million |
Market revenue in 2030 | USD 528.2 million |
Growth rate | 21.2% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.78% in 2023. Horizon Databook has segmented the Canada crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Canada’s market is expected to register significant growth throughout the forecast period. Factors such as development & advancement initiatives by research institutions & the government and increased research activities to improve CRISPR adoption are expected to propel market growth in Canada.
In addition, several conferences and meetings on CRISPR technology conducted in this region have helped increase awareness, subsequently propelling revenue generation. For instance, the annual CRISPR meeting was hosted first time in Québec City, Canada, in July 2019.
In September 2015, Toronto's Hospital for Sick Children received funding from Duchenne UK for research in CRISPR to develop gene-editing therapies to treat genetic diseases in children, such as Duchenne muscular dystrophy.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada crispr and cas genes market , including forecasts for subscribers. This country databook contains high-level insights into Canada crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account